NRXP NRX Pharmaceuticals Inc

Price (delayed)

$2.48

Market cap

$26.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.14

Enterprise value

$32M

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination ...

Highlights
NRXP's EPS is up by 45% year-on-year and by 22% since the previous quarter
NRX Pharmaceuticals's debt has decreased by 44% YoY and by 26% from the previous quarter
NRX Pharmaceuticals's quick ratio has plunged by 91% YoY and by 71% from the previous quarter
The company's equity fell by 28% QoQ

Key stats

What are the main financial stats of NRXP
Market
Shares outstanding
10.7M
Market cap
$26.54M
Enterprise value
$32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$25.29M
EBITDA
-$25.28M
Free cash flow
-$19.24M
Per share
EPS
-$3.14
Free cash flow per share
-$2.17
Book value per share
-$1.57
Revenue per share
$0
TBVPS
$0.43
Balance sheet
Total assets
$3.79M
Total liabilities
$18.86M
Debt
$6.78M
Equity
-$15.07M
Working capital
-$15.51M
Liquidity
Debt to equity
-0.45
Current ratio
0.18
Quick ratio
0.07
Net debt/EBITDA
-0.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-233%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NRXP stock price

How has the NRX Pharmaceuticals stock price performed over time
Intraday
2.48%
1 week
-0.4%
1 month
-26.63%
1 year
-34.91%
YTD
-46.09%
QTD
1.64%

Financial performance

How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.4M
Net income
-$25.64M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 36% YoY and by 12% from the previous quarter
NRX Pharmaceuticals's net income has increased by 31% YoY and by 15% from the previous quarter

Growth

What is NRX Pharmaceuticals's growth rate over time

Valuation

What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NRXP's EPS is up by 45% year-on-year and by 22% since the previous quarter
The company's equity fell by 28% QoQ

Efficiency

How efficient is NRX Pharmaceuticals business performance
NRX Pharmaceuticals's ROA has plunged by 64% YoY and by 20% from the previous quarter

Dividends

What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRXP.

Financial health

How did NRX Pharmaceuticals financials performed over time
The total assets is 80% less than the total liabilities
NRX Pharmaceuticals's quick ratio has plunged by 91% YoY and by 71% from the previous quarter
The total assets has plunged by 83% YoY and by 48% from the previous quarter
NRX Pharmaceuticals's debt is 145% more than its equity
The debt to equity has soared by 99% YoY and by 42% from the previous quarter
NRX Pharmaceuticals's debt has decreased by 44% YoY and by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.